|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,209.00 GBX | -0.49% |
|
-3.20% | -22.00% |
| 11/03 | FTSE 100 falls as Iran war lifts inflation fears | AN |
| 11/03 | Hikma chief people officer buys almost GBP75,000 in shares | AN |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Injectables | 98Cr | 105.3Cr | 114.1Cr | 120.3Cr | 130.6Cr | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Gross Profit | 56Cr | 58Cr | 62Cr | 66Cr | 69Cr | |||||
D&A | 2.3Cr | 3Cr | - | - | - | |||||
Operating Income | 38Cr | 40Cr | 43Cr | 44Cr | 47Cr | |||||
Hikma Rx | 74Cr | 82Cr | 67Cr | 94Cr | 102.6Cr | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Gross Profit | 34Cr | 39Cr | 26Cr | 39Cr | 36Cr | |||||
D&A | 90L | 3.3Cr | - | - | - | |||||
Operating Income | 16Cr | 20Cr | 10Cr | 19Cr | 17Cr | |||||
Branded | 61Cr | 67Cr | 69Cr | 71Cr | 77Cr | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Gross Profit | 31Cr | 33Cr | 35Cr | 37Cr | 40Cr | |||||
D&A | 1Cr | 1Cr | - | - | - | |||||
Operating Income | 13Cr | 12Cr | 15Cr | 17Cr | 19Cr | |||||
Medical Consumables | ||||||||||
Others | 70L | 1.1Cr | 1.3Cr | 2.1Cr | 2.6Cr | |||||
Gross Profit | 20L | 50L | 70L | -30L | -10L | |||||
Operating Income | - | 20L | 30L | -90L | -90L | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Operating Income | -9.8Cr | -9.2Cr | -8.4Cr | -9Cr | -9.9Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 140.6Cr | 151.1Cr | 143.3Cr | 172.6Cr | 188.7Cr | |||||
Total Assets | - | 108.3Cr | 130.5Cr | 130.1Cr | 151.8Cr | |||||
CAPEX | -8.9Cr | -5.6Cr | -4.6Cr | -4.6Cr | -4.9Cr | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | -1.6Cr | -2.3Cr | -2Cr | -2.7Cr | -3.6Cr | |||||
Other Middle East and North Africa | 43Cr | 50Cr | 38Cr | 37Cr | 47Cr | |||||
Total Assets | - | 32Cr | 22Cr | 7.5Cr | 9.3Cr | |||||
Saudi Arabia | 22Cr | 22Cr | 24Cr | 26Cr | 30Cr | |||||
Total Assets | - | - | - | 7.1Cr | 7.5Cr | |||||
Europe and Rest of the World | 16Cr | 19Cr | 21Cr | 21Cr | 22Cr | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | -6.7Cr | -6.6Cr | -7.2Cr | -9.6Cr | -8Cr | |||||
Algeria | - | - | 13Cr | 19Cr | 21Cr | |||||
Total Assets | - | - | 8.5Cr | 10Cr | 12Cr | |||||
North America (Excl. United States) | - | - | - | 2.3Cr | 2.4Cr | |||||
Total Assets | - | - | - | 4.2Cr | 4Cr | |||||
Total Assets | - | - | - | 8.9Cr | 9.2Cr | |||||
United Kingdom | 60L | 60L | 80L | 1.1Cr | 1.3Cr | |||||
Total Assets | - | 8.1Cr | 2Cr | 1.1Cr | 70L | |||||
Egypt | 12Cr | 13Cr | 12Cr | 9.3Cr | - | |||||
Total Assets | - | 5.2Cr | 8.9Cr | 4.7Cr | 4.1Cr | |||||
Total Assets | - | 14Cr | 13Cr | 15Cr | 15Cr | |||||
Total Assets | - | 36Cr | 35Cr | 35Cr | 34Cr | |||||
Total Assets | - | - | - | 3.6Cr | 3Cr |
- Stock Market
- Equities
- HIK Stock
- Financials Hikma Pharmaceuticals PLC
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















